On 18 March, the Critical Path Institute (C-Path) and H.Lundbeck A/S (Lundbeck) announced a new data sharing collaboration, with Lundbeck contributing clinical trial data from over 2,500 participants to the Critical Path for Alzheimer’s Disease (CPAD) consortium database. The data contribution agreement between C-Path and Lundbeck is supported by Gates Ventures.
C-Path is a non-profit public-private partnership with the US Food and Drug Administration (FDA), formed in 2005 with the aim of advancing medical innovation and creating new tools to speed up the drug development process. CPAD, a C-Path programme focused on Alzheimer’s disease (AD) and related neurological disorders, manages a patient-level database that currently contains data and information from more than 14,500 patients and clinical trial participants. The contribution of Lundbeck datasets will expand this database, and CPAD aims to add further patient-level datasets over the coming months. The Lundbeck datasets are particularly valuable as they stem from Phase II and Phase III trials that evaluated idalopiridine (a selective 5-HT antagonist) as an adjunct to cholinesterase inhibitor therapy in mild to moderate AD.
Together with the other patient-level datasets in the CPAD database, data contributed by Lundbeck will help CPAD create new disease progression models across the timecourse of AD development. In addition, datasets will be made securely available to qualified researchers upon request.
